



May 13, 2026

Company name: Mitsubishi Chemical Group Corporation
 Representative: Manabu Chikumoto
 Representative Corporate Executive Officer,
 President & Chief Executive Officer
 Listed on The Prime Market TSE (stock
 code:4188)
 Contact: [Press inquiries]
 Corporate Communications Office
 Tel: (+81) (0)3-6748-7140
 [IR inquiries]
 Investor Relations Office
 Tel: (+81) (0)3-6748-7120

Notice Regarding Differences between Financial Results Forecast and Financial Result for the Fiscal Year Ended March 31, 2026 and Voluntary Return of Executive Officer Remuneration

Mitsubishi Chemical Group Corporation hereby announces differences between its financial results forecast for the fiscal year ended March 31, 2026 announced on February 5, 2026 and financial results announced today as follows.

1. Differences between consolidated financial results forecast and financial results for fiscal 2025, ended March 31, 2026 (April 1, 2025 - March 31, 2026)

(Billions of yen; unless otherwise noted)

	Sales revenue	Core operating income	Operating income	Net Income	Net income attributable to owners of the parent	Basic earnings per share (yen)
Previous forecast (A) (announced on February 5, 2026)	3,672.0	250.0	70.0	114.8	47.0	34.29
Results (B)	3,704.0	225.0	30.1	78.4	11.8	8.63
Difference (B – A)	32.0	(25.0)	(39.9)	(36.4)	(35.2)	
Difference (%)	0.9	(10.0)	(57.0)	(31.7)	(74.8)	
Reference: Results for fiscal 2025	3,947.6	228.8	141.6	105.6	45.0	31.64

Notes:

- Net income before taxes: ¥36.0 billion (previous forecast); ¥0.7 billion (result)
 - Core operating income is operating income (loss) after excluding certain gains and expenses attributable to non-recurring factors.
 - Upon the approval at MCG's Ordinary General Meeting of Shareholders held on June 25, 2025 with regard to the absorption-type split agreement to transfer all shares and related assets of Mitsubishi Tanabe Pharma Corporation (hereinafter "MTPC"), MTPC and its subsidiaries and affiliates have been transferred on July 1, 2025. MTPC and its subsidiaries and affiliates have been classified as discontinued operations since the beginning of the fiscal year, and sales revenue, core operating income, operating income and income before taxes, and for the consolidated financial results and forecast for fiscal 2025 and financial results for fiscal 2024 represent the amounts of continued operations excluding discontinued operations.
- Mitsubishi Tanabe Pharma Corporation changed its corporate name to Tanabe Pharma Corporation as of December 1, 2025.

2. Reason for Differences

The Company recognized impairment losses on the Soarnol production facilities of Mitsubishi Chemical UK Limited in the Specialty Materials segment, and on ethylene oxide and ethylene glycols production facilities of Mitsubishi Chemical Corporation in the Basic Materials & Polymers segment. Primarily due to these factors, core operating income and all income levels below fell short of the previously announced forecast figures.

Reference:**Core operating income by segment (April 1, 2025 - March 31, 2026)**

(Billions of yen)

	Results	Previous forecast	Difference
Specialty Materials	32.3	65.0	(32.7)
MMA & Derivatives	(1.5)	(1.0)	(0.5)
Basic Materials & Polymers	(4.2)	(1.0)	(3.2)
Industrial Gases	200.7	189.0	11.7
Others	(2.3)	(2.0)	(0.3)
Total	225.0	250.0	(25.0)

3. Voluntary return of executive officer remuneration

Given the aforementioned recognition of an impairment loss on Soarnol production facilities, the Company's Representative Corporate Executive Officer, President and Chief Executive Officer, and the executive officer responsible for the relevant business at Mitsubishi Chemical Corporation, a consolidated subsidiary of the Company, offered to voluntarily return their remuneration. The Company and Mitsubishi Chemical Corporation decided to accept their offer.

(1) Details of the voluntary return of executive officer remuneration

Representative Corporate Executive Officer, President and Chief Executive Officer:

20% of monthly compensation

Head of Films & Performance Materials, Managing Executive Officer, Mitsubishi Chemical Corporation:

20% of monthly compensation

(2) Applicable period

Six months